Regenerative medicine company Orthocell Limited (ASX:OCC) reports that the highly regarded “Tissue Engineering” Journal has published a positive pre-clinical and clinical results for the use of CelGro®in enhancing repair of critical bone defects.
The paper is entitled “Collagen Membrane for Guided Bone Regeneration in Dental and Orthopedic Applications”.
Lead author and chief investigator Dr Brent Allan commented: “My experience in using CelGro®in dental implant procedures has given me the confidence to use it in more complex Orthognathic procedures. These surgeries are life changing and technically demanding. Predictable and high-quality bone regeneration is of upmost importance to deliver functional, as well as aesthetically pleasing outcomes for patients.”
Orthocell Managing Director, Paul Anderson, said CelGro®is an ideal membrane for Guided Bone Regeneration (GBR) not only in oral maxillofacial reconstructive surgery but also in orthopedic applications such as open tibial fractures and incidences of non-union fractures.
In May 2018, Orthocell announced the results of a clinical study designed to evaluate the performance of CelGro®in dental GBR treatment. Dental GBR is a standard procedure used routinely in clinical practice, to preserve and restore bone volume to facilitate the subsequent placement of dental implants.
The clinical study involved a two-stage dental implant procedure with GBR in 10 patients (involving 16 dental implants). Bone defects were covered with the CelGro®collagen membrane after bone void filling. Various assessments related to performance of the CelGro®collagen membrane was evaluated up to 6 months post GBR treatment.
Top line data indicated that use of CelGro®resulted in successful bone regeneration within 4 to 6 months of the procedure, enabling the next stage of implant surgery (placement of the crown). Further, the void-filling material was fully integrated into the newly regenerated bone, with no reported complications or adverse events.
We are delighted with the publication of the positive pre-clinical and clinical results indicating CelGro®aids in accelerating the repair of difficult to treat critical bone defects,” Mr Anderson said.
“These are exciting results as they further demonstrate the potential to extend the applications of CelGro®representing an area of significant clinical interest to the maxillofacial and orthopaedic community.”
Lead author and chief investigator Dr Brent Allan commented: “My experience in using CelGro®in dental implant procedures has given me the confidence to use it in more complex Orthognathic procedures. These surgeries are life changing and technically demanding. Predictable and high-quality bone regeneration is of upmost importance to deliver functional, as well as aesthetically pleasing outcomes for patients.”
